Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma?

• Main Authors: Sviatoslav Chekhun (Author), Assumpció Lopez-Paradís (Author), Aintzane Urbizu (Author), Teresa Morán (Author), Anabel Mañes (Author), Marc Cucurull (Author), Carlos Martínez-Barenys (Author), Iris Teruel (Author), Gloria Moragas (Author), Enric Carcereny (Author), Ana Maria Muñoz Mármol (Author), Maria Saigí (Author)
• Format: Book
• Published: Open Exploration Publishing Inc., 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have shown impressive results in EGFR mutant lung cancer (LC) patients in terms of disease control rate with a positive impact on overall survival. Nevertheless, after months of treatment with targeted therapy...